Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30407118 | 0.77 | KDM4E (0.35) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL293045 | 0.76 | KDM4E (0.37) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15761031 | 0.76 | KDM4E (0.37) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL30485934 | 0.76 | KDM4E (0.37) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL30096256 | 0.76 | KDM4E (0.38) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2006247 | 0.74 | KDM4E (0.33) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL276958 | 0.74 | P2RY6 (0.34) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3069884 | 0.74 | KDM4E (0.37) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL293044 | 0.74 | KDM4E (0.33) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1077043 | 0.74 | P2RY6 (0.34) | KDM4EMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102827124-B | Coumarin derivatives and pharmaceutical composition thereof and purposes | BEIJING HANMEI PHARMACEUTICAL CO., LTD. (CN) | 2015-10-21 | — | — | CN | claimed |
| CN-103214414-B | The diamine derivative of opticity and manufacture method thereof | SANKYO CO. (JP) | 2016-02-17 | — | — | CN | disclosed |
| CN-103380131-B | As the heteroaryl compound of 5-HT4 receptors ligand | SUVEN LIFE SCIENCES LTD. (IN) | 2015-12-02 | — | — | CN | disclosed |
| CN-105026372-A | Histone demethylase inhibitors | QUANTICEL PHARMACEUTICALS INC | 2015-11-04 | — | — | CN | disclosed |
| CN-102827124-B | Coumarin derivatives and pharmaceutical composition thereof and purposes | BEIJING HANMEI PHARMACEUTICAL CO., LTD. (CN) | 2015-10-21 | — | — | CN | disclosed |
| CN-104610215-A | Preparation method of nebivolol intermediates and preparation method of nebivolol | ZHEJIANG HISOAR PHARMACEUTICAL CO LTD | 2015-05-13 | — | — | CN | disclosed |
| CN-103880827-A | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RES INC | 2014-06-25 | — | — | CN | disclosed |
| CN-101641014-B | Poly (ADP-ribose) polymerase inhibitors | ABBVIE INC | 2013-12-18 | — | — | CN | disclosed |
| CN-103214414-A | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2013-07-24 | — | — | CN | disclosed |
| CN-101263110-B | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2013-04-03 | — | — | CN | disclosed |
| CN-101081843-B | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB | 2010-10-13 | — | — | CN | disclosed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
| CN-101081843-A | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| CN-1264839-C | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-19 | — | — | CN | disclosed |
| CN-1494545-A | Non-nucleoside reverse transcriptase inhibitors | ά | 2004-05-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | KDM4E 2673/4885MEN1 2308/4885ALDH1A1 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.